Literature DB >> 17030710

Vascular endothelial growth factor a in eyes with uveal melanoma.

Guy S O Missotten1, Irene C Notting, Reinier O Schlingemann, Henry J Zijlmans, Chun Lau, Paul H C Eilers, Jan E E Keunen, Martine J Jager.   

Abstract

OBJECTIVES: To determine the presence of vascular endothelial growth factor A (VEGF-A) in the aqueous humor of eyes with uveal melanoma and to identify its source.
METHODS: The VEGF-A concentrations were determined in aqueous humor samples obtained after enucleation from 74 eyes with untreated uveal melanoma and from 8 eyes with treated uveal melanoma. Patient survival and clinical and histopathological tumor variables were compared. In situ hybridization, Western blot analysis, and enzyme-linked immunosorbent assay were used to determine expression of VEGF-A in tumor tissue and in overlying retina.
RESULTS: Aqueous VEGF-A concentrations ranged from 18 to 826 pg/mL in 74 untreated eyes, while concentrations in 30 control eyes were significantly lower (median, 50.1 pg/mL) (P<.001). Concentrations in 8 treated eyes were much higher (median, 364 pg/mL). In situ hybridization on tissue sections and Western blot analysis and enzyme-linked immunosorbent assay on tissue extracts revealed VEGF-A in uveal melanoma tissue and in retinal tissue.
CONCLUSIONS: Uveal melanoma is associated with increased concentrations of VEGF-A in aqueous humor. Aqueous VEGF-A concentration correlates with largest basal tumor diameter and with the tumor height. In eyes with uveal melanoma, tumor and retinal tissues are sources of VEGF-A.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030710     DOI: 10.1001/archopht.124.10.1428

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  46 in total

1.  Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration.

Authors:  Long V Ly; Inge H G Bronkhorst; Els van Beelen; Johannes Vrolijk; Andrew W Taylor; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

3.  Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Nikolaos E Bechrakis; Gregor Willerding; Georgios St Charitoudis; Michael H Foerster; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Clin Exp Metastasis       Date:  2011-10-09       Impact factor: 5.150

4.  Endodrainage, Tumor Photocoagulation, and Silicone Oil Tamponade for Primary Exudative Retinal Detachment due to Choroidal Melanoma Persisting after Proton Beam Therapy.

Authors:  Ira Seibel; Dino Cordini; Gregor Willerding; Aline Isabel Riechardt; Antonia Maria Joussen
Journal:  Ocul Oncol Pathol       Date:  2014-07-22

5.  Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF.

Authors:  Rajesh K Sharma; Cheryl L Rowe-Rendleman
Journal:  Neurochem Res       Date:  2010-12-07       Impact factor: 3.996

6.  Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Authors:  Anne Sudaka; Antoine Susini; Cristiana Lo Nigro; Jean-Louis Fischel; Nicolas Toussan; Patricia Formento; Federica Tonissi; Laura Lattanzio; Elvio Russi; Marie-Christine Etienne-Grimaldi; Marco Merlano; Gérard Milano
Journal:  Invest New Drugs       Date:  2012-06-20       Impact factor: 3.850

7.  Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.

Authors:  Hua Yang; Martine J Jager; Hans E Grossniklaus
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

8.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

9.  Intravitreal bevacizumab for macular edema due to proton beam radiotherapy: Favorable results shown after eighteen months follow-up.

Authors:  Eleni Loukianou; Dimitrios Brouzas; Eleni Georgopoulou; Chrysanthi Koutsandrea; Michael Apostolopoulos
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

10.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.